)

Poolbeg Pharma (POLB) investor relations material
Poolbeg Pharma Study Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Clinical program highlights
POLB 001, a P38 MAP kinase inhibitor, is advancing as a preventative for cancer immunotherapy-induced CRS, with phase 2A trial preparation at an advanced stage and interim data expected in summer 2026.
The phase 2A open-label, single-arm trial will enroll about 30 relapsed/refractory multiple myeloma patients at leading UK cancer centers, using an approved bispecific antibody supplied at no cost.
The trial will be conducted by Accelerating Clinical Trials Ltd (ACT), with Dr Emma Searle as Chief Investigator.
POLB 001 has demonstrated favorable safety, broad cytokine inhibition, and preserved immune function in preclinical and phase 1 studies.
No further preclinical studies are required before the phase 2A trial; the trial is designed to deliver rapid, actionable results.
Market need and differentiation
CRS affects up to 70% of patients receiving CAR-T or bispecific therapies, creating a bottleneck in access and straining healthcare resources.
Current treatments for CRS are reactive, with no approved preventative options; POLB 001 aims to fill this gap as an oral, non-immunosuppressive therapy.
POLB 001's mechanism targets a broad range of cytokines, potentially offering superior efficacy over existing agents like tocilizumab.
The addressable market is estimated at over $10 billion, with significant interest from pharma partners.
POLB 001 could enable wider, community-based administration of immunotherapies, reducing hospital stays and improving patient quality of life.
Strategic and financial outlook
The company is well-capitalized with a cash runway into 2027, supporting near-term clinical milestones.
Partnering is a core focus, with ongoing outreach to major pharma companies and flexible monetization options including licensing or program sale.
Additional pipeline includes an oral GLP-1 obesity program, with proof-of-concept data expected in the first half of next year.
The team has a strong track record in clinical development and transactions, aiming to generate compelling human data to drive value.
Focus remains on high-value programs addressing critical unmet medical needs and large markets.
Next Poolbeg Pharma earnings date

Next Poolbeg Pharma earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage